Shanghai Registry of Acute Coronary Events

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

20000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation

NCT00445263

CORONARY DISEASE

TERMINATED PHASE4

Tirofiban in Stenting for Long Coronary Lesion

NCT01498003

Coronary Artery Disease

COMPLETED PHASE4

Serp-1 for the Treatment of Acute Coronary Syndrome

NCT00243308

Unstable Angina Coronary Atherosclerosis Coronary Restenosis

TERMINATED PHASE2

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

NCT03236311

Microvascular Coronary Artery Disease

TERMINATED PHASE2

Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention

NCT04571580

Acute ST-segment Elevation Myocardial Infarction

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

consecutive patients with STEMI who presented symptoms within 12 hours and treated by primary PCI in Shanghai, were enrolled in the prospective sysytem. Several strategies were applied in these patients, including physician vs. patient transfer strategy, upsteam vs. downstream strategy, Firebird stent vs. Excel stent (bio-absorbable SES), etc. Once the patient was randomized to one of these study, he will be denied to the others. Clinical and angiographic outcomes were compared, with the final purpose to find an optimal strategy in treating AMI patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy

drug-eluting stent

Intervention Type DEVICE

drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

2

patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI

drug-eluting stent

Intervention Type DEVICE

drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

Tirofiban

Intervention Type DRUG

upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading

3

patients with non-ST-elevation ACS treated by immediate PCI

drug-eluting stent

Intervention Type DEVICE

drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

4

patients with non ST-elevation ACS treated by elective PCI

drug-eluting stent

Intervention Type DEVICE

drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

5

STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.

No interventions assigned to this group

6

STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

drug-eluting stent

drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

Intervention Type DEVICE

Tirofiban

upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cypher stent Taxus stent Firebird stent Excel stent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment

Exclusion Criteria

* non ACS patients;
* complicated with other lethal disease
* predicted life span less than 12 months
* known allergy history to any anti-platelet or anti-thrombin medicine
* unconscious at the time of arrival at the hospital

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No